Trials / Completed
CompletedNCT06553040
The Effect of Albumin Value, HALP Score, and LCR Value on Predicting Survival and Recurrence in Patients With Pancreatic Adenocarcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 87 (actual)
- Sponsor
- Ege University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to investigate whether the albumin value and the ratios of biochemical markers; hemoglobin, albumin, lymphocyte and platelet (HALP score) and lymphocyte-C-reactive protein ratio (LCR) can predict the survival and recurrence of the disease in patients with pancreatic adenocarcinoma.
Conditions
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2021-12-01
- Completion
- 2023-01-01
- First posted
- 2024-08-14
- Last updated
- 2024-08-14
Source: ClinicalTrials.gov record NCT06553040. Inclusion in this directory is not an endorsement.